
|Articles|September 1, 2022
US-based development, testing and fill/finish capacity is now available
Author(s)August Bioservices
Since 2020, the CDMO landscape has undergone significant changes. Dearth of fill/finish capacity in the US, exacerbated by COVID and vaccine production, caused market dislocation but also opportunity. With insights gathered through a blind, independent “voice of the customer” industry survey, discover what over 300 decision makers had to say about post-COVID trends and outsourcing plans. Among the intriguing responses captured in the survey – nearly 80% of respondents expressed they were open to, or actively looking for, new CRO/CDMO partners over the past 12 months.
Trending on Pharmaceutical Technology
1
The FDA Moves to Modernize Drug Manufacturing Registration
2
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
3
PharmTech Weekly Roundup–July 10, 2026
4
Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies
5